<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168438</url>
  </required_header>
  <id_info>
    <org_study_id>208470</org_study_id>
    <secondary_id>ADP-0011-008</secondary_id>
    <secondary_id>KEYNOTE-487</secondary_id>
    <nct_id>NCT03168438</nct_id>
  </id_info>
  <brief_title>Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma</brief_title>
  <official_title>Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel&#xD;
      (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated following an internal review of the company's research and development&#xD;
    portfolio&#xD;
  </why_stopped>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Actual">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">July 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)and serious adverse events (SAEs)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>AEs and SAEs will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory paramaters</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Blood samples will be collected for the assessment of hematology, clinical chemistry and coagulation parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal cardiac assessments by electrocardiogram (ECG)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>The following cardiac parameters will be measured: Heart rate, heart rhythm, PR Interval, RR Interval, QRS Interval and QT interval corrected (QTc) (Fridericia's or Bazett's correction)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Overall Response Rate is defined as the proportion of participants with a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR) using IMWG uniform response criteria for MM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Time to response is defined as the time from date of T-cell infusion to initial date of response of the participant who achieved confirmed sCR, CR, VGPR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for all participants who achieve at least PR</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Duration of response is defined as the time from the initial date of response of the participants who achieved confirmed sCR, CR, VGPR or PR to the date of progressive disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Progression free survival is defined as the time from the date of T cell infusion until first documented sign of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum persistence (Cmax)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Serial blood samples will be collected at specific timepoints for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Serial blood samples will be collected at specific timepoints for evaluation of Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time curve from zero to time t (AUC 0-t)</measure>
    <time_frame>Up to 108 weeks</time_frame>
    <description>Serial blood samples will be collected at specific timepoints for evaluation of AUC (0 to t).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1: Letetresgene autoleucel (GSK3377794)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letetresgene autoleucel</intervention_name>
    <description>Letetresgene autoleucel (GSK3377794) as an IV infusion</description>
    <arm_group_label>Arm 1: Letetresgene autoleucel (GSK3377794)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letetresgene autoleucel with pembrolizumab</intervention_name>
    <description>Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks</description>
    <arm_group_label>Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.</description>
    <arm_group_label>Arm 1: Letetresgene autoleucel (GSK3377794)</arm_group_label>
    <arm_group_label>Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.</description>
    <arm_group_label>Arm 1: Letetresgene autoleucel (GSK3377794)</arm_group_label>
    <arm_group_label>Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is available as an IV infusion</description>
    <arm_group_label>Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=18 years of age or older on the date of signing informed consent.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of secretory multiple myeloma with myeloma markers&#xD;
             at levels defined in the protocol.&#xD;
&#xD;
          -  Documented diagnosis of relapsed and refractory multiple myeloma (RRMM) (at least 3&#xD;
             prior regimens and responsive to at least 1, and refractory to most recent prior&#xD;
             therapies, which must have included one or more than one drug from each of the&#xD;
             following drug classes: an immunomodulatory imide drug (IMiD), proteasome inhibitor,&#xD;
             alkylator (unless the participant is ineligible or contraindicated to receive an&#xD;
             alkylator), CD 38 monoclonal antibody, and glucocorticoid as separate lines or a&#xD;
             combined line of therapy.- Left ventricular ejection fraction (LVEF) &gt;= 50%. Lower&#xD;
             LVEF (&gt;= 40%) permissible if formal cardiologic evaluation reveals no evidence for&#xD;
             clinically significant functional impairment.&#xD;
&#xD;
          -  Meets protocol criteria for patients who have previously received checkpoint&#xD;
             inhibitors or other immuno-oncology agents.&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1.&#xD;
&#xD;
          -  Participant is HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 positive as determined by&#xD;
             a designated central laboratory.&#xD;
&#xD;
          -  Participant has confirmed sufficient expression of NY-ESO-1 and/or LAGE-1a as&#xD;
             determined by a designated central laboratory.&#xD;
&#xD;
          -  In the Investigator's opinion, the participant is fit for cell collection.&#xD;
&#xD;
          -  Participant has adequate organ function and cell counts as described in the protocol.&#xD;
&#xD;
          -  Participants previously treated with BCMA therapy (BCMA chimeric antigen receptor&#xD;
             (CAR)-T, antibody-drug conjugate (ADC), or other type of BCMA-targeted therapy) must&#xD;
             have progressed from this therapy prior to attending the Baseline visit prior to&#xD;
             beginning lymphodepletion.&#xD;
&#xD;
          -  Contraception use by male and female participant meets protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has only plasmacytomas, plasma cell leukemia, monoclonal gammopathy of undetermined&#xD;
             significance (MGUS), smoldering multiple myeloma (SMM), non-secretory myeloma or&#xD;
             primarily amyloidosis.&#xD;
&#xD;
          -  Previously received anti- programmed death (PD)-1, anti-PD-ligand (L)1, or anti-PD-L2&#xD;
             inhibitor.&#xD;
&#xD;
          -  Previously participated in Merck pivotal trial NCT02576977: Study of Pomalidomide and&#xD;
             Low Dose Dexamethasone With or Without Pembrolizumab in Refractory or RRMM.&#xD;
&#xD;
          -  Had a prior allogeneic stem cell transplant.&#xD;
&#xD;
          -  Has ongoing toxicity from previous anticancer therapy.&#xD;
&#xD;
          -  Had a major surgery within 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Has history of allergic reactions to fludarabine, cyclophosphamide or agents similar&#xD;
             to fludarabine, cyclophosphamide or other agents used in the study.&#xD;
&#xD;
          -  Known history of myelodysplasia.&#xD;
&#xD;
          -  Current active liver or biliary disease.&#xD;
&#xD;
          -  Known history of chronic active hepatitis or liver cirrhosis.&#xD;
&#xD;
          -  Participant has an active viral infection.&#xD;
&#xD;
          -  History of severe immune disease, including non-infectious pneumonitis, requiring&#xD;
             steroids or other immunosuppressive treatments.&#xD;
&#xD;
          -  Active immune-mediated diseases.&#xD;
&#xD;
          -  Prior or active demyelinating disease.&#xD;
&#xD;
          -  Evidence or history of significant cardiac disease.&#xD;
&#xD;
          -  Evidence or history of other significant, hepatic, renal, ophthalmologic, psychiatric,&#xD;
             or gastrointestinal disease.&#xD;
&#xD;
          -  Participants with concomitant second malignancies (except adequately treated&#xD;
             non-melanomatous skin cancers, carcinoma in situ of the breast, treated superficial&#xD;
             bladder cancer or prostate cancer, or in situ cervical cancers ) not in complete&#xD;
             remission.&#xD;
&#xD;
          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Participants with previously treated brain metastases may be eligible.&#xD;
&#xD;
          -  Active bacterial or systemic viral or fungal infections.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Cannot meet washout periods for prior radiotherapy, chemotherapy or other&#xD;
             protocol-specified therapies.&#xD;
&#xD;
          -  More than 2 years have passed since the participant's last leukapheresis collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed and Refractory Multiple Myeloma</keyword>
  <keyword>T Cell Receptor</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>NY-ESO-1</keyword>
  <keyword>Leukapheresis</keyword>
  <keyword>Adoptive TCR T-cell therapy</keyword>
  <keyword>Letetresgene autoleucel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

